X4 Pharmaceuticals is rated BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending into 2028. XFOR's primary value lies in its 4WARD Phase 3 trial in ...

Delays and detours are a frustrating part of the commute. When they happen during already scheduled service changes, riders are left wondering where to turn. Nancy Guthrie update: Ex-FBI agent details ...

China’s economic performance has been stellar over the past three decades, with remarkable and persistent high growth that lifted the economy from low-income to upper-middle-income status. Measured at ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...